Stockreport

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus BioSciences, Inc.  (CHRS) 
Last coherus biosciences, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.coherus.com
PDF - Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. [Read more]